Cargando…
An Optimized Framework for Cancer Prediction Using Immunosignature
BACKGROUND: Cancer is a complex disease which can engages the immune system of the patient. In this regard, determination of distinct immunosignatures for various cancers has received increasing interest recently. However, prediction accuracy and reproducibility of the computational methods are limi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116316/ https://www.ncbi.nlm.nih.gov/pubmed/30181964 http://dx.doi.org/10.4103/jmss.JMSS_2_18 |
_version_ | 1783351578294484992 |
---|---|
author | Firouzabadi, Fatemeh Safaei Vard, Alireza Sehhati, Mohammadreza Mohebian, Mohammadreza |
author_facet | Firouzabadi, Fatemeh Safaei Vard, Alireza Sehhati, Mohammadreza Mohebian, Mohammadreza |
author_sort | Firouzabadi, Fatemeh Safaei |
collection | PubMed |
description | BACKGROUND: Cancer is a complex disease which can engages the immune system of the patient. In this regard, determination of distinct immunosignatures for various cancers has received increasing interest recently. However, prediction accuracy and reproducibility of the computational methods are limited. In this article, we introduce a robust method for predicting eight types of cancers including astrocytoma, breast cancer, multiple myeloma, lung cancer, oligodendroglia, ovarian cancer, advanced pancreatic cancer, and Ewing sarcoma. METHODS: In the proposed scheme, at first, the database is normalized with a dictionary of normalization methods that are combined with particle swarm optimization (PSO) for selecting the best normalization method for each feature. Then, statistical feature selection methods are used to separate discriminative features and they were further improved by PSO with appropriate weights as the inputs of the classification system. Finally, the support vector machines, decision tree, and multilayer perceptron neural network were used as classifiers. RESULTS: The performance of the hybrid predictor was assessed using the holdout method. According to this method, the minimum sensitivity, specificity, precision, and accuracy of the proposed algorithm were 92.4 ± 1.1, 99.1 ± 1.1, 90.6 ± 2.1, and 98.3 ± 1.0, respectively, among the three types of classification that are used in our algorithm. CONCLUSION: The proposed algorithm considers all the circumstances and works with each feature in its special way. Thus, the proposed algorithm can be used as a promising framework for cancer prediction with immunosignature. |
format | Online Article Text |
id | pubmed-6116316 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-61163162018-09-04 An Optimized Framework for Cancer Prediction Using Immunosignature Firouzabadi, Fatemeh Safaei Vard, Alireza Sehhati, Mohammadreza Mohebian, Mohammadreza J Med Signals Sens Original Article BACKGROUND: Cancer is a complex disease which can engages the immune system of the patient. In this regard, determination of distinct immunosignatures for various cancers has received increasing interest recently. However, prediction accuracy and reproducibility of the computational methods are limited. In this article, we introduce a robust method for predicting eight types of cancers including astrocytoma, breast cancer, multiple myeloma, lung cancer, oligodendroglia, ovarian cancer, advanced pancreatic cancer, and Ewing sarcoma. METHODS: In the proposed scheme, at first, the database is normalized with a dictionary of normalization methods that are combined with particle swarm optimization (PSO) for selecting the best normalization method for each feature. Then, statistical feature selection methods are used to separate discriminative features and they were further improved by PSO with appropriate weights as the inputs of the classification system. Finally, the support vector machines, decision tree, and multilayer perceptron neural network were used as classifiers. RESULTS: The performance of the hybrid predictor was assessed using the holdout method. According to this method, the minimum sensitivity, specificity, precision, and accuracy of the proposed algorithm were 92.4 ± 1.1, 99.1 ± 1.1, 90.6 ± 2.1, and 98.3 ± 1.0, respectively, among the three types of classification that are used in our algorithm. CONCLUSION: The proposed algorithm considers all the circumstances and works with each feature in its special way. Thus, the proposed algorithm can be used as a promising framework for cancer prediction with immunosignature. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6116316/ /pubmed/30181964 http://dx.doi.org/10.4103/jmss.JMSS_2_18 Text en Copyright: © 2018 Journal of Medical Signals & Sensors http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Firouzabadi, Fatemeh Safaei Vard, Alireza Sehhati, Mohammadreza Mohebian, Mohammadreza An Optimized Framework for Cancer Prediction Using Immunosignature |
title | An Optimized Framework for Cancer Prediction Using Immunosignature |
title_full | An Optimized Framework for Cancer Prediction Using Immunosignature |
title_fullStr | An Optimized Framework for Cancer Prediction Using Immunosignature |
title_full_unstemmed | An Optimized Framework for Cancer Prediction Using Immunosignature |
title_short | An Optimized Framework for Cancer Prediction Using Immunosignature |
title_sort | optimized framework for cancer prediction using immunosignature |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116316/ https://www.ncbi.nlm.nih.gov/pubmed/30181964 http://dx.doi.org/10.4103/jmss.JMSS_2_18 |
work_keys_str_mv | AT firouzabadifatemehsafaei anoptimizedframeworkforcancerpredictionusingimmunosignature AT vardalireza anoptimizedframeworkforcancerpredictionusingimmunosignature AT sehhatimohammadreza anoptimizedframeworkforcancerpredictionusingimmunosignature AT mohebianmohammadreza anoptimizedframeworkforcancerpredictionusingimmunosignature AT firouzabadifatemehsafaei optimizedframeworkforcancerpredictionusingimmunosignature AT vardalireza optimizedframeworkforcancerpredictionusingimmunosignature AT sehhatimohammadreza optimizedframeworkforcancerpredictionusingimmunosignature AT mohebianmohammadreza optimizedframeworkforcancerpredictionusingimmunosignature |